More positive data for Rituxan in rare autoimmune condition

14 June 2019

Positive topline results from the Phase III PEMPHIX study show Rituxan (rituximab) compares favorably as a therapy for the rare, serious and potentially life-threatening condition pemphigus vulgaris (PV).

Sold by Roche (ROG: SIX) subsidiary Genentech, Rituxan is the first biologic therapy approved for PV in the USA, and the first major advance in the treatment of the disease in decades.

The original approval was based on the Ritux 3 clinical trial. European regulators gave the nod for this indication in March 2019. The option, which is marketed in Europe as MabThera, is now approved to treat four autoimmune diseases in the USA and Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK